Share Price and Basic Stock Data
Last Updated: November 28, 2025, 10:39 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Cian Healthcare Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹15.8 Cr and a share price of ₹6.31. The company has reported fluctuating sales figures over the past four fiscal years, with revenues peaking at ₹77.87 Cr in March 2022, followed by a decline to ₹68.59 Cr in March 2023 and further to ₹61.70 Cr in March 2024. This downward trend in revenue raises concerns about the company’s ability to maintain growth in a competitive market. A closer look at expenses reveals a similar pattern, which stood at ₹73.52 Cr in March 2022, then decreased to ₹55.60 Cr in March 2023, and ₹51.30 Cr in March 2024. The operating profit margin (OPM) has varied significantly, reaching a high of 18.94% in March 2023 before settling at 16.86% in March 2024. This inconsistency in revenue and profit margins indicates potential challenges in managing operational efficiency and market demand.
Profitability and Efficiency Metrics
Cian Healthcare’s profitability metrics reflect a challenging financial landscape. The net profit recorded for March 2024 was ₹0.25 Cr, a significant decline from ₹2.03 Cr in March 2023, highlighting a downward trend in profitability. The company’s earnings per share (EPS) also fell to ₹0.10 in March 2024 from ₹0.81 in March 2023, indicating diminishing returns for shareholders. The return on equity (ROE) stood at 0.43% and the return on capital employed (ROCE) at 5.22%, both of which are below industry averages. In terms of operational efficiency, the cash conversion cycle (CCC) was reported at 235.85 days, which is relatively high compared to typical sector ranges, suggesting inefficiencies in managing working capital. The interest coverage ratio (ICR) was recorded at 1.95x, indicating that the company is barely able to meet its interest obligations, which could limit its ability to invest in growth opportunities.
Balance Sheet Strength and Financial Ratios
Cian Healthcare’s balance sheet reflects a cautious financial position, with no reported borrowings or reserves, which limits financial flexibility. The price-to-book value (P/BV) ratio stood at 0.89x, suggesting that the stock is trading below its book value, which may attract value investors. The company’s total debt-to-equity ratio was recorded at 0.96x, indicating a moderate level of leverage, while the current ratio of 1.09x suggests that the company has sufficient liquidity to meet short-term obligations. However, the quick ratio of 0.46x raises concerns about the company’s ability to cover its liabilities without relying on inventory sales. The efficiency ratios, including the asset turnover ratio at 0.38%, indicate that the company is underperforming in utilizing its assets to generate revenue, which could hinder future growth prospects if not addressed.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Cian Healthcare reflects a significant shift in investor confidence, particularly among promoters. The promoters’ stake has decreased from 70.89% in September 2021 to 27.11% in March 2024, indicating a potential loss of confidence in the company’s future prospects. Public shareholding has increased substantially, rising from 29.11% to 72.89% in the same period, suggesting that retail investors are taking a more prominent role. However, the absence of Foreign Institutional Investors (FIIs) and the negligible stake of Domestic Institutional Investors (DIIs) at 0.00% may point to a lack of institutional confidence in the company’s performance. The total number of shareholders has increased, reaching 1,662 by September 2025, which may indicate growing interest at the retail level despite the declining promoter shareholding.
Outlook, Risks, and Final Insight
Looking ahead, Cian Healthcare faces a mixed outlook with several risks and strengths. On the one hand, the decline in sales and profitability metrics raises concerns about its competitive positioning in the pharmaceuticals market. Additionally, the company’s high cash conversion cycle and low ROE may hinder its ability to attract investment and drive growth. Conversely, the low P/BV ratio might present a buying opportunity for value-oriented investors. The increase in public shareholding could signify potential for renewed interest and support for the company’s strategic direction. However, the lack of institutional backing remains a significant risk. To improve its outlook, Cian Healthcare needs to focus on enhancing operational efficiency, managing costs effectively, and restoring profitability to regain investor confidence and stabilize its market position.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Cian Healthcare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 149 Cr. | 118 | 247/84.3 | 32.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,425 Cr. | 406 | 479/192 | 91.6 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 42.5 Cr. | 29.0 | 29.3/17.0 | 101 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,561.99 Cr | 1,174.44 | 52.22 | 202.44 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric |
|---|
| Sales |
| Expenses |
| Operating Profit |
| OPM % |
| Other Income |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| Net Profit |
| EPS in Rs |
Last Updated: August 19, 2025, 9:10 pm
Below is a detailed analysis of the quarterly data for Cian Healthcare Ltd based on the most recent figures () and their trends compared to the previous period:
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:39 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Sales | 57.09 | 73.73 | 77.87 | 68.59 | 61.70 |
| Expenses | 49.74 | 61.74 | 73.52 | 55.60 | 51.30 |
| Operating Profit | 7.35 | 11.99 | 4.35 | 12.99 | 10.40 |
| OPM % | 12.87% | 16.26% | 5.59% | 18.94% | 16.86% |
| Other Income | 0.79 | 0.07 | 0.47 | 0.73 | 1.12 |
| Interest | 7.22 | 7.92 | 6.55 | 6.30 | 6.00 |
| Depreciation | 4.45 | 3.45 | 4.27 | 5.43 | 5.47 |
| Profit before tax | -3.53 | 0.69 | -6.00 | 1.99 | 0.05 |
| Tax % | 7.37% | 91.30% | -7.83% | -2.01% | -400.00% |
| Net Profit | -3.79 | 0.05 | -5.53 | 2.03 | 0.25 |
| EPS in Rs | -1.62 | 0.02 | -2.21 | 0.81 | 0.10 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 101.32% | -11160.00% | 136.71% | -87.68% |
| Change in YoY Net Profit Growth (%) | 0.00% | -11261.32% | 11296.71% | -224.39% |
Cian Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2020-2021 to 2023-2024.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 53% |
| TTM: | -8600% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -43% |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 2:56 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Debtor Days | 127.80 | 93.56 | 125.24 | 139.58 | 121.15 |
| Inventory Days | 267.18 | 312.78 | 299.94 | 399.93 | 485.99 |
| Days Payable | 220.03 | 209.37 | 270.46 | 295.80 | 371.29 |
| Cash Conversion Cycle | 174.95 | 196.98 | 154.73 | 243.71 | 235.85 |
| Working Capital Days | 14.77 | 16.14 | 38.30 | 40.66 | 26.27 |
| ROCE % | 6.78% | 0.50% | 6.91% | 5.22% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.10 | 0.81 | -2.32 | 0.02 | -1.62 |
| Diluted EPS (Rs.) | 0.10 | 0.81 | -2.32 | 0.02 | -1.62 |
| Cash EPS (Rs.) | 2.29 | 2.98 | -0.50 | 1.50 | 0.28 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 23.10 | 23.00 | 22.19 | 24.92 | 24.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 23.10 | 23.00 | 22.19 | 24.93 | 24.91 |
| Revenue From Operations / Share (Rs.) | 24.68 | 27.44 | 31.15 | 31.56 | 24.44 |
| PBDIT / Share (Rs.) | 4.52 | 5.20 | 1.91 | 5.17 | 3.47 |
| PBIT / Share (Rs.) | 2.34 | 3.03 | 0.20 | 3.69 | 1.57 |
| PBT / Share (Rs.) | 0.01 | 0.79 | -2.37 | 0.38 | -1.48 |
| Net Profit / Share (Rs.) | 0.10 | 0.81 | -2.21 | 0.02 | -1.62 |
| NP After MI And SOA / Share (Rs.) | 0.10 | 0.81 | -2.21 | 0.02 | -1.62 |
| PBDIT Margin (%) | 18.32 | 18.94 | 6.14 | 16.37 | 14.20 |
| PBIT Margin (%) | 9.46 | 11.03 | 0.65 | 11.69 | 6.41 |
| PBT Margin (%) | 0.07 | 2.90 | -7.61 | 1.21 | -6.05 |
| Net Profit Margin (%) | 0.41 | 2.95 | -7.10 | 0.07 | -6.63 |
| NP After MI And SOA Margin (%) | 0.41 | 2.95 | -7.10 | 0.07 | -6.63 |
| Return on Networth / Equity (%) | 0.44 | 3.53 | -9.97 | 0.09 | -6.51 |
| Return on Capital Employeed (%) | 6.14 | 7.94 | 0.53 | 8.66 | 3.39 |
| Return On Assets (%) | 0.15 | 1.26 | -3.33 | 0.03 | -2.41 |
| Long Term Debt / Equity (X) | 0.47 | 0.51 | 0.68 | 0.64 | 0.78 |
| Total Debt / Equity (X) | 0.96 | 1.06 | 1.14 | 1.22 | 1.26 |
| Asset Turnover Ratio (%) | 0.38 | 0.44 | 0.43 | 0.49 | 0.00 |
| Current Ratio (X) | 1.09 | 1.14 | 1.14 | 1.10 | 1.12 |
| Quick Ratio (X) | 0.46 | 0.57 | 0.56 | 0.56 | 0.71 |
| Inventory Turnover Ratio (X) | 0.95 | 0.96 | 1.24 | 1.54 | 0.00 |
| Interest Coverage Ratio (X) | 1.95 | 2.28 | 0.74 | 1.56 | 1.14 |
| Interest Coverage Ratio (Post Tax) (X) | 1.04 | 1.34 | 0.15 | 1.03 | 0.47 |
| Enterprise Value (Cr.) | 106.16 | 129.47 | 109.32 | 94.69 | 104.74 |
| EV / Net Operating Revenue (X) | 1.72 | 1.89 | 1.40 | 1.28 | 1.83 |
| EV / EBITDA (X) | 9.39 | 9.96 | 22.84 | 7.84 | 12.91 |
| MarketCap / Net Operating Revenue (X) | 0.83 | 1.02 | 0.61 | 0.35 | 0.61 |
| Price / BV (X) | 0.89 | 1.22 | 0.85 | 0.45 | 0.60 |
| Price / Net Operating Revenue (X) | 0.83 | 1.02 | 0.61 | 0.35 | 0.61 |
| EarningsYield | 0.00 | 0.02 | -0.11 | 0.00 | -0.10 |
After reviewing the key financial ratios for Cian Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For Diluted EPS (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For Cash EPS (Rs.), as of Mar 24, the value is 2.29. This value is below the healthy minimum of 3. It has decreased from 2.98 (Mar 23) to 2.29, marking a decrease of 0.69.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 23.10. It has increased from 23.00 (Mar 23) to 23.10, marking an increase of 0.10.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 23.10. It has increased from 23.00 (Mar 23) to 23.10, marking an increase of 0.10.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 24.68. It has decreased from 27.44 (Mar 23) to 24.68, marking a decrease of 2.76.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 4.52. This value is within the healthy range. It has decreased from 5.20 (Mar 23) to 4.52, marking a decrease of 0.68.
- For PBIT / Share (Rs.), as of Mar 24, the value is 2.34. This value is within the healthy range. It has decreased from 3.03 (Mar 23) to 2.34, marking a decrease of 0.69.
- For PBT / Share (Rs.), as of Mar 24, the value is 0.01. This value is within the healthy range. It has decreased from 0.79 (Mar 23) to 0.01, marking a decrease of 0.78.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 2. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 2. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For PBDIT Margin (%), as of Mar 24, the value is 18.32. This value is within the healthy range. It has decreased from 18.94 (Mar 23) to 18.32, marking a decrease of 0.62.
- For PBIT Margin (%), as of Mar 24, the value is 9.46. This value is below the healthy minimum of 10. It has decreased from 11.03 (Mar 23) to 9.46, marking a decrease of 1.57.
- For PBT Margin (%), as of Mar 24, the value is 0.07. This value is below the healthy minimum of 10. It has decreased from 2.90 (Mar 23) to 0.07, marking a decrease of 2.83.
- For Net Profit Margin (%), as of Mar 24, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 2.95 (Mar 23) to 0.41, marking a decrease of 2.54.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 0.41. This value is below the healthy minimum of 8. It has decreased from 2.95 (Mar 23) to 0.41, marking a decrease of 2.54.
- For Return on Networth / Equity (%), as of Mar 24, the value is 0.44. This value is below the healthy minimum of 15. It has decreased from 3.53 (Mar 23) to 0.44, marking a decrease of 3.09.
- For Return on Capital Employeed (%), as of Mar 24, the value is 6.14. This value is below the healthy minimum of 10. It has decreased from 7.94 (Mar 23) to 6.14, marking a decrease of 1.80.
- For Return On Assets (%), as of Mar 24, the value is 0.15. This value is below the healthy minimum of 5. It has decreased from 1.26 (Mar 23) to 0.15, marking a decrease of 1.11.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.47. This value is within the healthy range. It has decreased from 0.51 (Mar 23) to 0.47, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.96. This value is within the healthy range. It has decreased from 1.06 (Mar 23) to 0.96, marking a decrease of 0.10.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.38. It has decreased from 0.44 (Mar 23) to 0.38, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 24, the value is 1.09. This value is below the healthy minimum of 1.5. It has decreased from 1.14 (Mar 23) to 1.09, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 24, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.57 (Mar 23) to 0.46, marking a decrease of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.95. This value is below the healthy minimum of 4. It has decreased from 0.96 (Mar 23) to 0.95, marking a decrease of 0.01.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 1.95. This value is below the healthy minimum of 3. It has decreased from 2.28 (Mar 23) to 1.95, marking a decrease of 0.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 1.04. This value is below the healthy minimum of 3. It has decreased from 1.34 (Mar 23) to 1.04, marking a decrease of 0.30.
- For Enterprise Value (Cr.), as of Mar 24, the value is 106.16. It has decreased from 129.47 (Mar 23) to 106.16, marking a decrease of 23.31.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.72. This value is within the healthy range. It has decreased from 1.89 (Mar 23) to 1.72, marking a decrease of 0.17.
- For EV / EBITDA (X), as of Mar 24, the value is 9.39. This value is within the healthy range. It has decreased from 9.96 (Mar 23) to 9.39, marking a decrease of 0.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 23) to 0.83, marking a decrease of 0.19.
- For Price / BV (X), as of Mar 24, the value is 0.89. This value is below the healthy minimum of 1. It has decreased from 1.22 (Mar 23) to 0.89, marking a decrease of 0.33.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 23) to 0.83, marking a decrease of 0.19.
- For EarningsYield, as of Mar 24, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to 0.00, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cian Healthcare Ltd:
- Net Profit Margin: 0.41%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.14% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.44% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.04
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.96
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.41%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Milkat No. 3339, Block No.1, From South Side, Pune Maharashtra 412308 | cs@cian.co https://www.cian.co |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suraj Shriniwas Zanwar | Managing Director |
| Mrs. Swati Maheshwari | Independent Director |
| Mr. Paresh Arun Shah | Non Executive Director |
| Mr. Sunil Saini | Independent Director |